Rodman & Renshaw Maintains NxStage Medical Market Perform

Rodman & Renshaw maintained its NxStage Medical NXTM Market Perform rating in a research report published today. In the report, Rodman & Renshaw states, "Given the risks we see on the horizon, [NXTM] is fairly valued at the current levels. We believe the key risks to this story are execution risk, reimbursement risk and market risk." Shares of NXTM closed today at $19,78, down 11.78% from Wednesday's market close.